Literature DB >> 2158405

Altered glycosylation in Madin-Darby canine kidney (MDCK) cells after transformation by murine sarcoma virus.

E A Bruyneel1, H Debray, M De Mets, M M Mareel, J Montreuil.   

Abstract

The changes in glycosylation of an immortalized epithelial cell line (MDCK) before and after progression towards a more malignant phenotype have been studied. The parental MDCK-3 cells were immortalized after long-term passage in vitro and have shown no tendency for spontaneous acquisition of malignancy-related phenotypes such as tumorigenicity, invasion and metastasis. They conserved morphological and functional characteristics of the epithelial tissue of origin. The ras-MDCK cells acquired the fully malignant phenotype after transformation with a Harvey murine sarcoma virus; they were immortalized, invasive in vitro and produced invasive and also metastatic tumors after subcutaneous injection into nude mice. Using immobilized lectins and gel chromatography, before and after liberation of O-linked glycans from the peptide moieties and also after removal of terminal sialic acid, we have found differences in the glycosylpeptides of both whole cells and cell surface trypsinates from ras-MDCK cultures as compared to the parental MDCK-3 cultures: (i) more sialic acid in the N-linked tri- and tetra-antennary structures; (ii) more fucosylation in the N-glycosylpeptides; (iii) more bi-antennary N-glycosylpeptides and less O-linked glycans; and (iv) a lower molecular weight of the O-linked glycans probably due to a decreased sialylation. It is concluded that alterations in sialylation and fucosylation of the cell surface exposed glycans accompanied progression of MDCK-3 cells towards a more malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2158405     DOI: 10.1007/BF00141255

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  29 in total

Review 1.  Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture.

Authors:  L A Liotta
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

2.  Modification of cell surface carbohydrates and invasive behavior by an alkyl lysophospholipid.

Authors:  J G Bolscher; D C Schallier; H van Rooy; G A Storme; L A Smets
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

Review 3.  Carbohydrates of the tumor cell surface.

Authors:  L A Smets; W P Van Beek
Journal:  Biochim Biophys Acta       Date:  1984

4.  Characterization of a deficiency in fucose metabolism in lectin-resistant variants of a murine tumor showing altered tumorigenic and metastatic capacities in vivo.

Authors:  J W Dennis; R S Kerbel
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

5.  Revertants of Ha-MuSV-transformed MDCK cells express reduced levels of p21 and possess a more normal phenotype.

Authors:  F J Darfler; T Y Shih; M C Lin
Journal:  Exp Cell Res       Date:  1986-02       Impact factor: 3.905

6.  Novel fucolipids accumulating in human adenocarcinoma. III. A hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3NeuAcV3III3Fuc2nLc6).

Authors:  Y Fukushi; E Nudelman; S B Levery; S Hakomori; H Rauvala
Journal:  J Biol Chem       Date:  1984-08-25       Impact factor: 5.157

7.  Glycoconjugates of murine tumor lines with different metastatic capacities. I. Differences in fucose utilization and in glycoprotein patterns.

Authors:  R Schwartz; V Schirrmacher; P F Mühlradt
Journal:  Int J Cancer       Date:  1984-04-15       Impact factor: 7.396

8.  Decreased fucose incorporation in cell surface carbohydrates is associated with inhibition of invasion.

Authors:  J G Bolscher; E A Bruyneel; H Van Rooy; D C Schallier; M M Mareel; L A Smets
Journal:  Clin Exp Metastasis       Date:  1989 Sep-Oct       Impact factor: 5.150

9.  Transfection by human oncogenes: concomitant induction of tumorigenicity and tumor-associated membrane alterations.

Authors:  J G Collard; W P van Beek; J W Janssen; J F Schijven
Journal:  Int J Cancer       Date:  1985-02-15       Impact factor: 7.396

10.  Role for carbohydrate structures in TGF-beta 1 latency.

Authors:  K Miyazono; C H Heldin
Journal:  Nature       Date:  1989-03-09       Impact factor: 49.962

View more
  6 in total

1.  Anticancer Activity of Chloroform Extract and Sub-fractions of Nepeta deflersiana on Human Breast and Lung Cancer Cells: An In vitro Cytotoxicity Assessment.

Authors:  Mai M Al-Oqail; Ebtesam S Al-Sheddi; Maqsood A Siddiqui; Javed Musarrat; Abdulaziz A Al-Khedhairy; Nida N Farshori
Journal:  Pharmacogn Mag       Date:  2015-10       Impact factor: 1.085

2.  Development and characterization of a stable bovine intestinal sub-epithelial myofibroblast cell line from ileum of a young calf.

Authors:  Tirth Uprety; Brionna B Spurlin; Linto Antony; Chithra Sreenivasan; Alan Young; Feng Li; Michael B Hildreth; Radhey S Kaushik
Journal:  In Vitro Cell Dev Biol Anim       Date:  2019-06-10       Impact factor: 2.416

Review 3.  The invasive phenotypes.

Authors:  M M Mareel; F M Van Roy; P De Baetselier
Journal:  Cancer Metastasis Rev       Date:  1990-07       Impact factor: 9.264

4.  Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus.

Authors:  J E Hansen; C Nielsen; M Arendrup; S Olofsson; L Mathiesen; J O Nielsen; H Clausen
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

5.  An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus.

Authors:  J E Hansen; H Clausen; S L Hu; J O Nielsen; S Olofsson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

6.  N-Linked Glycan Branching and Fucosylation Are Increased Directly in Hcc Tissue As Determined through in Situ Glycan Imaging.

Authors:  Connor A West; Mengjun Wang; Harmin Herrera; Hongyan Liang; Alyson Black; Peggi M Angel; Richard R Drake; Anand S Mehta
Journal:  J Proteome Res       Date:  2018-09-05       Impact factor: 4.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.